Anti-Human CD269/TNFRSF17/BCMA Antibody (SAA0086)

Catalog No.

FHF92410

Species reactivity

Human

Host species

Human

Isotype

IgG1, kappa

Clonality

Monoclonal

Conjugation

Unconjugated

Applications

ELISA, FCM

Target

Tumor necrosis factor receptor superfamily member 17, TNFRSF17, CD269, B-cell maturation protein, BCMA, BCM

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q02223

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

SAA0086

Note

For research use only.

Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-mediated Antitumor Responses In Vivo., PMID:34253590

BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression., PMID:34301753

Endogenous soluble receptors sBCMA and sTACI: biomarker, immunoregulator and hurdle for therapy in multiple myeloma., PMID:34330018

[The Significance of CD319 and CD269 in the Detection of Immunophenotyping and Minimal Residual Disease in Multiple Myeloma Patients]., PMID:34362502

Targeting BCMA in Multiple Myeloma., PMID:34432234

Serum B-Cell maturation antigen is an independent prognostic marker in previously untreated chronic lymphocytic leukemia., PMID:35525334

Teclistamab in Relapsed or Refractory Multiple Myeloma., PMID:35661166

Expression levels and patterns of B-cell maturation antigen in newly diagnosed and relapsed multiple myeloma patients from Indian subcontinent., PMID:36346307

B cell-specific mAb-siRNA conjugates improve experimental myasthenia., PMID:36640636

Serum levels and significance of soluble B-cell maturation antigen in childhood-onset systemic lupus erythematosus with renal involvement., PMID:36914971

Impact of Treatment Modality and Route of Administration on Cytokine Release Syndrome in Relapsed or Refractory Multiple Myeloma: A Meta-Analysis., PMID:38459622

Soluble B-cell maturation antigen in lacrimal fluid as a potential biomarker and mediator of keratopathy in multiple myeloma., PMID:38572568

Real-World Data on Therapies for Relapsed or Refractory Multiple Myeloma: Key Data from ASH 2023-A Podcast., PMID:38642197

Effectiveness and infectious complications of BCMA T-cell engagers in treating multiple myeloma: Real-world evidence from Sweden., PMID:38651177

Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study., PMID:38657201

Therapeutic potential of third-generation chimeric antigen receptor T cells targeting B cell maturation antigen for treating multiple myeloma., PMID:38683232

Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma., PMID:38728378

BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial., PMID:38777376

Current progress of CAR-T-cell therapy for patients with multiple myeloma., PMID:38777913

BCMA/CD47-directed universal CAR-T cells exhibit excellent antitumor activity in multiple myeloma., PMID:38783333

Comparison of infectious complications with BCMA-directed therapies in multiple myeloma., PMID:38821925

Beyond BCMA: newer immune targets in myeloma., PMID:38865708

Anti-BCMA-engineered exosomes for bortezomib-targeted delivery in multiple myeloma., PMID:38875465

Informing the Recommended Phase III Dose of Alnuctamab, a CD3 × BCMA T-Cell Engager, Using Population Pharmacokinetics and Exposure-Response Analysis., PMID:38938115

Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins., PMID:38961233

Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma., PMID:39043638

Management of Toxicities Associated with BCMA, GPRC5D, and FcRH5-Targeting Bispecific Antibodies in Multiple Myeloma., PMID:39145912

Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies., PMID:39172760

Current status of BAFF targeting immunotherapy in B-cell neoplasm., PMID:39222149

Interferon Regulatory Factor 4: An Alternative Marker for Plasma Cells in Daratumumab-Treated Patients With Multiple Myeloma., PMID:39267340

Preclinical Evaluation of STI-8811, a Novel Antibody-Drug Conjugate Targeting BCMA for the Treatment of Multiple Myeloma., PMID:39292169

B-Cell Maturation Antigen-Directed Immunotherapies for the Treatment of Relapsed/Refractory Multiple Myeloma: A Review of the Literature and Implications for Clinical Practice., PMID:39373355

Single-cell analysis of the multiple myeloma microenvironment after γ-secretase inhibition and CAR T-cell therapy., PMID:39374522

Phase 1 first-in-human study of MEDI2228, a BCMA-targeted ADC, in patients with relapsed refractory multiple myeloma., PMID:39404476

B-Cell Maturation Antigen (BCMA) as a Biomarker and Potential Treatment Target in Systemic Lupus Erythematosus., PMID:39409173

Trispecific anti-CD3/BCMA/CD38 antibodies for multiple myeloma: a patent evaluation of US20240132615., PMID:39460602

Enhanced cytotoxicity in multiple myeloma via T cells armed with bispecific T cell engager targeting B-cell maturation antigen on cancer cells and CD3 on T cells., PMID:39467352

BCMA-Directed MRD Detection as a Predictor of Relapse after BCMA CAR T in Multiple Myeloma., PMID:39516088

Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy., PMID:39632797

Clinical updates of B‑cell maturation antigen‑targeted therapy in multiple myeloma (MM) and relapsed/refractory MM (Review)., PMID:39670288

Targeting human plasma cells using regulated BCMA CAR T cells eliminates circulating antibodies in humanized mice., PMID:39673129

Anti-BCMA and GPRC5D bispecific antibodies in relapsed/refractory primary plasma cell leukemia: a case report., PMID:39676854

Dual-targeted STAb-T cells secreting BCMA and CD19 T cell engagers for improved control of haematological cancers., PMID:39723764

Update on B-cell maturation antigen-directed therapies in AL amyloidosis., PMID:39748220

Mechanisms for resistance to BCMA-targeted immunotherapies in multiple myeloma., PMID:39818472

Population Pharmacokinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antigen Receptor T-cell Product, in Patients with Relapsed/Refractory Multiple Myeloma., PMID:39836430

BCMA-targeted therapies for multiple myeloma: latest updates from 2024 ASH annual meeting., PMID:40025529

BCMA-targeted therapies in multiple myeloma: advances, challenges and future prospects., PMID:40338452

An Anti-BCMA Affibody Affinity Protein for Therapeutic and Diagnostic Use in Multiple Myeloma., PMID:40507995

Document Download

Anti-Human CD269/TNFRSF17/BCMA Antibody (SAA0086).pdf